IP Library › Granted Patent US 8,759,522
Granted Patent B2
US 8,759,522 · App. 12/964,289 · Granted Jun 24, 2014

Inhibitors of protein tyrosine kinase activity

Inventors: Michael Mannion (Montreal, CA); Stephane Raeppel (St-Lazare, CA); Stephen William Claridge (Montreal, CA); Frederic Gaudette (Laval, CA); Lijie Zhan (Montreal, CA); Ljubomir Isakovic (Beaconsfield, CA); Oscar Mario Saavedra (Montreal, CA); Tetsuyuki Uno (Okayama, JP); Masashi Kishida (Hyogo, JP); Arkadii Vaisburg (Kirkland, CA)
Assignee: Methylgene Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,759,522
App. No.
12/964,289
Granted
Jun 24, 2014
Kind
B2
Abstract

This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.

Claims (11)

1. A compound selected from the group consisting of

and pharmaceutically acceptable salts thereof.

2. The compound according to claim 1 , wherein the compound is

3. The compound according to claim 1 , wherein the compound is

4. The compound according to claim 1 , wherein the compound is

5. The compound according to claim 1 , wherein the compound is

6. A composition comprising a compound according to claim 1 , and a pharmaceutically acceptable carrier.

7. The composition according to claim 6 , wherein the compound is

8. The composition according to claim 6 , wherein the compound is

9. The composition according to claim 6 , wherein the compound is

10. The composition according to claim 6 , wherein the compound is

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2013
From: OTSUKA PHARMACEUTICAL CO. LTD.
To: METHYLGENE INC.
Reel/Frame 030926/0937 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2010
From: METHYLGENE INC.
To: OTSUKA PHARMACEUTICAL CO. LTD.
Reel/Frame 025503/0131 →
Continuity (3)
Continuation 12920676
Provisional Application 61034005 · Mar 5, 2008
Related Publication 20110077240A1 · Mar 31, 2011